SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna Group is trending after its Q4 earnings report, which showed a net loss fueled by higher credit loss provisions despite revenue growth, triggered a significant stock price decline. This has ignited a fierce debate among investors, with some warning of a "falling knife" in the struggling fintech sector while others view it as a deeply "oversold" opportunity supported by strong partnerships.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending as it reopens deal talks with Paramount Skydance following a sweetened offer including a breakup fee coverage and a ticking fee, escalating the bidding war while shareholders await a vote on Netflix's board-recommended acquisition.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following significant news of EU approval for its ANKTIVA bladder cancer therapy and a strategic distribution partnership across Europe, alongside an updated submission to the US FDA for expanded indication. The community is highly engaged, anticipating a major short squeeze and substantial long-term growth while actively discussing market makers attempting to suppress the stock around options expiry.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

Starfighters Space Inc. ($FJET) is trending on investor excitement surrounding its upcoming NYSE Opening Bell ceremony, with community chatter focusing on its low float and high short interest for a potential squeeze. The company's positioning in the commercial aerospace sector, including discussions around hypersonic tech contracts, is driving active debate and bullish sentiment for significant gains.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

The FDA's decision to review Moderna's seasonal flu vaccine application is driving investor optimism and a notable share price surge, while community sentiment remains highly active, weighing this regulatory win against its expanding oncology pipeline and a significant patent infringement trial.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is trending following a strong earnings report and its expanding role in the agentic AI market, fueling a short squeeze as bulls anticipate further upside, while bears warn of an impending pullback or offering amid notable insider selling.

Deere & Co. engages in the manufacture and distribution of equipment used in agriculture, construction, forestry, and turf care. It operates through the following segments: Agriculture and Turf, Construction and Forestry, and Financial Services. The Agriculture and Turf segment focuses on the distribution and manufacture of a full line of agriculture and turf equipment and related service parts. The Construction and Forestry segment offers machines and service parts used in construction, earthmoving, road building, material handling and timber harvesting. The Financial Services segment finances sales and leases by John Deere dealers of new and used agriculture and turf equipment and construction and forestry equipment. The company was founded by John Deere in 1837 and is headquartered in Moline, IL.

Deere & Co.

Deere & Co

Deere & Co. is experiencing significant conversation after its latest earnings report revealed strong revenue growth and an increased full-year outlook, with management signaling the agricultural cycle's bottom in the current year. While many celebrate this potential breakout, community discussions also highlight concerns over the stock's valuation and declining profitability despite the positive top-line performance.

Booking Holdings, Inc. engages in the provision of online travel and related solutions. The firm offers services through the following brands: Booking.com, Priceline, Agoda, KAYAK, and OpenTable. It provides accommodation reservations including hotels, hostels, apartments, vacation rentals, and other properties. The company was founded by Jay Scott Walker on July 18, 1997, and is headquartered in Norwalk, CT.

Booking Holdings Inc

Booking Holdings is trending following a significant post-earnings sell-off, despite reporting strong quarterly results, increasing its dividend, and announcing a 25-for-1 stock split. The community is actively debating whether the dip presents a buying opportunity or reflects deeper market concerns regarding potential AI disruption to the online travel sector.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after a major competitor, Corcept Therapeutics, received an FDA rejection for its next-gen Cushing's syndrome drug, a development the community views as a significant competitive advantage for XERS's Recorlev. Investors are actively discussing this "irrational" dip as a buying opportunity, anticipating strong Q4 earnings, bullish 2026 guidance, and the advancement of its promising XP-8121 pipeline.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is seeing high trading volume and significant price volatility after an earnings report that missed revenue and EPS estimates but showcased robust total order and marketplace gross order value growth. This contradictory performance has ignited intense debate among investors, with optimists pointing to strong business expansion and a post-earnings rally, while skeptics emphasize the valuation, cautious Q1 outlook, and analyst price target cuts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Biotech-focused investor Cormorant Asset Management rebuilt its stake above 6% on Tuesday.</li><li>Cormorant disclosed ownership of 4.36 million shares, up from about 2 million shares in October.</li><li>Retail sentiment flipped to ‘extremely bullish’ from ‘extremely bearish’ on Stocktwits, and message volume surged more than 900%.</li></ul>Shares of MoonLake Immunotherapeutics, Inc. jumped 11% on Tuesday, marking the stock’s biggest rally in over a month, after a biotech-focused investment firm rebuilt its stake amid heightened buzz among retail traders speculating a possible takeover.<h2 class="st-heading-2">Cormorant Lifts MoonLake Stake Above 6%</h2>A Schedule 13G filing on Tuesday showed Cormorant Asset Management reported ownership of 4.36 million Class A ordinary shares in MoonLake Immunotherapeutics, representing a 6.1% stake as of Dec. 31, 2025. The stake increased from about 2 million shares, or 3.14%, disclosed in October 2025 filings, after the firm had previously reduced its position below the 5% reporting threshold.Cormorant Asset Management is a biotech-specialised investment management firm with stakes in Praxis Precision Medicines, BridgeBio Oncology Therapeutics, Edgewise Therapeutics, and Metsera, which was acquired last year by Pfizer, among others.According to data from Quiver Quantitative, the firm reported holdings in 43 stocks as of Sept. 30, 2025, with an estimated portfolio value of about $1.45 billion.<h2 class="st-heading-2">FDA Momentum Builds Around Sonelokimab</h2>Earlier this month, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to the company’s lead investigational therapy, Sonelokimab, for moderate-to-severe palmoplantar pustulosis. The company plans to pursue a biologics license application for Sonelokimab in hidradenitis suppurativa in the second half of 2026.Last month, MoonLake said a Type B meeting with the FDA confirmed its clinical evidence strategy for Sonelokimab in hidradenitis suppurativa. Following that update, several brokerages raised price targets or upgraded the stock, though&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mltx-stock-erases-most-of-2025-loses-wall-street-retail-bets-on-fda-feedback-for-sonelokima/cmU1QhGR471">Goldman Sachs</a> downgraded MoonLake to ‘Sell’ last month, citing “high risk” around approvability in hidradenitis suppurativa.The company is scheduled to host an investor day on Feb. 23, at which it plans to provide updates on the clinical development and regulatory pathway for Sonelokimab across multiple inflammatory disease indications.<h2 class="st-heading-2">Stocktwits Buzz Erupts Around MLTX</h2>On Stocktwits, retail sentiment for MLTX flipped to ‘extremely bullish’ from ‘extremely bearish’ over the past day amid over a 900% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/mltx_ss_png_b0740594f9.webp" alt="mltx ss.png" width="971" height="140"><figcaption>MLTX sentiment and message volume as of February 17 | Source: Stocktwits</figcaption></figure>One user said the Cormorant filing has “fundamentally broken” the short thesis. “Cormorant—who knows the science better than anyone—just admitted the "Bear Thesis" was wrong by buying back in at $12-$16.”<stembedurl>https://stocktwits.com/septrading/message/645184471</stembedurl>Another user said, “I can’t stop thinking that we get a PR of some sort, even a little teaser, PM tomorrow AM” ahead of the company’s investor day.<stembedurl>https://stocktwits.com/BOOPIE2020/message/645177386</stembedurl>A third user said, “I have to say that something may be coming..This price action today was solid coupled with the high after hours volume. Someone is accumulating.”<stembedurl>https://stocktwits.com/TDMF123/message/645174457</stembedurl>A separate user said they were watching for either a buyout announcement or positive regulatory news this week, while another argued MoonLake would need to trade higher before attracting interest from a large pharmaceutical acquirer.<stembedurl>https://stocktwits.com/Warren_8/message/645090086</stembedurl><stembedurl>https://stocktwits.com/Newcar/message/645134185</stembedurl>One user pointed to recent travel activity involving Merck’s corporate jet, hinting at a potential takeover by the big pharma firm and noted multiple trips to Zurich, where MoonLake is headquartered.&nbsp;<stembedurl>https://stocktwits.com/Bigpapa46/message/645006814</stembedurl>MLTX stock has risen 33% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites

Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.

Equity

GSA Capital Partners LLP Increases Holdings in Edgewise Therapeutics, Inc. $EWTX

GSA Capital Partners LLP increased its position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 315.2% during the 3rd quarter, according to the company in its most recent...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) has earned an average rating of "Moderate Buy" from the ten ratings firms that are covering the company, Marketbeat Ratings reports. One...

Edgewise Therapeutics (NASDAQ:EWTX) Upgraded at Wall Street Zen

Wall Street Zen raised shares of Edgewise Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday...

Edgewise Therapeutics Teases Phase 3 Sevasemten Readout, HCM Data Update at Guggenheim Conference

Edgewise Therapeutics (NASDAQ:EWTX) highlighted multiple upcoming milestones across its cardiac and neuromuscular programs during a presentation at Guggenheim's 2026 Healthcare Innovations...

Why Edgewise Therapeutics Stock Crushed the Market on Monday

Key PointsOne of the more bullish analysts tracking the company reiterated her enthusiastic buy recommendation on the biotech...

Edgewise Therapeutics (NASDAQ:EWTX) Sets New 12-Month High - Time to Buy?

Edgewise Therapeutics (NASDAQ:EWTX) Hits New 1-Year High - Here's Why...

Federated Hermes Inc. Decreases Stock Holdings in Edgewise Therapeutics, Inc. $EWTX

Federated Hermes Inc. reduced its position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 81.3% in the third quarter, according to the company in its most recent disclosure...

Edgewise Therapeutics (NASDAQ:EWTX) Downgraded by Wall Street Zen to Sell

Wall Street Zen lowered shares of Edgewise Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026

Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026...

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Current Price	$29.46
Prev Close	$30.15
Open	$30.01
Dividend Yield	0.00%
50-Day Moving Average	$26.37
Beta	1.36
Avg. Volume	1.16M
PE Ratio	-19.12

52-Week High	$31.29
52-Week Low	$10.60
Market Capitalization	$3.19B
EPS (Annual)	-$1.45
Price to Book	5.71
Revenue Per Employee	$0.00

EWTX
Edgewise Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EWTX News

EWTXEdgewise Therapeutics Inc